Výsledky vyhledávání - "P J, Bernink"

Prostaglandin E1 : electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil Investigators

Autor: J C, Somberg, V, Yelamanchi, J, Molnar, M, Aschermann, P J, Bernink, A, Caspi, A, Marmor, B, Rabinowitz, L, Reisin, W, Ruzyllo

Publikováno v: American journal of therapeutics. 4(11-12)

Prostaglandin E ( 1 ) (PGE ( 1 ) ), the active ingredient of the drug alprostadil-alpha-cyclodextrin, has been effective in mitigating the clinical manifestations of peripheral arterial occlusive disease (PAOD). PGE ( 1 ) often is administered to pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::df118569d5031a58a533375d2078a481
https://pubmed.ncbi.nlm.nih.gov/10423637

Zobrazit plný text záznamu

Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil Investigators

Autor: L, Reisin, A, Marmor, B, Rabinowitz, P J, Bernink, A, Caspi, W, Ruzyllo, J S, Borer

Publikováno v: American journal of therapeutics. 4(11-12)

To confirm the safety of prostaglandin E ( 1 ) (PGE ( 1 ) ) when administered in 100 mL normal saline to patients with severe peripheral occlusive disease (PAOD; Fontaine class III or IV) and concomitant compensated chronic congestive heart failure (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b8c883742599ff2cbdd2c6fc61c9f96a
https://pubmed.ncbi.nlm.nih.gov/10423632

Zobrazit plný text záznamu

[Prostaglandin E1 for prevention of contrast medium-induced kidney dysfunction]

Autor: J A, Koch, M, Sketch, J, Brinker, P J, Bernink

Publikováno v: RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 170(6)

Acute renal failure is a known complication of contrast media (CM) application in risk patients. Therefore an efficient prevention is highly desirable. The purpose of this pilot study was a) to demonstrate the efficacy and safety of prostaglandin E1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2c465afed617ee49eee6d69fb35f958c
https://pubmed.ncbi.nlm.nih.gov/10420905

Zobrazit plný text záznamu

A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group

Autor: R J, Viskoper, P J, Bernink, A, Schelling, A B, Ribeiro, I M, Kantola, M R, Wilkins, I, Kobrin

Publikováno v: Journal of human hypertension. 11(6)

To compare the efficacy and tolerability of mibefradil and amlodipine in patients with uncomplicated mild-to-moderate essential hypertension.A double-blind, randomised, parallel group multicentre trial.239 patients received 50 mg mibefradil or 5 mg a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5872fdf78f10164eb1d2d61da63f55e2
https://pubmed.ncbi.nlm.nih.gov/9249234

Zobrazit plný text záznamu

Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN)

Autor: R J, de Vries, A F, van den Heuvel, D J, Lok, R J, Claessens, P J, Bernink, W H, Pasteuning, J H, Kingma, P H, Dunselman

Publikováno v: International journal of cardiology. 57(2)

The gastrointestinal therapeutic system formulation of nifedipine enables a once-daily dosing resulting in predictable, relatively constant plasma concentrations. To evaluate the efficacy and safety of this formulation and to compare this with the be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b83c92c904be3f01a5b199458b29c608
https://pubmed.ncbi.nlm.nih.gov/9013266

Zobrazit plný text záznamu

Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group

Autor: P J, Bernink, G, Prager, A, Schelling, I, Kobrin

Publikováno v: Hypertension (Dallas, Tex. : 1979). 27(3 Pt 1)

Preclinical and initial clinical studies suggest that the novel calcium antagonist mibefradil has a unique combination of properties. Mibefredil was evaluated in a multicenter, double-blind, placebo-controlled, parallel group trial. After 4 weeks of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ce6bdc191323ce70a13791121003afc5
https://pubmed.ncbi.nlm.nih.gov/8698449

Zobrazit plný text záznamu

Long-term efficacy of diltiazem controlled release versus metoprolol in patients with stable angina pectoris

Autor: H W, Vliegen, E E, van der Wall, M G, Niemeyer, N J, Holwerda, P J, Bernink, P, de Weerd, A H, Bosma, L R, van der Wieken, A J, Timmermans, G P, Molhoek

Publikováno v: Journal of cardiovascular pharmacology. 18

In a randomized, double-blind, multicenter study, the efficacy of diltiazem controlled-release (CR) 120 mg b.i.d. was compared with metoprolol 100 mg b.i.d. in 56 patients with stable exertional angina pectoris. Fifty-one patients (28 receiving dilti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5f6a36931092f4b6a6b5cefa3cc0fab9
https://pubmed.ncbi.nlm.nih.gov/1725545

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání